Meningioma: A Comprehensive Clinical Guide for Patients

A diagnosis of a brain tumour is a profound moment in any patient’s life. As a neurosurgeon, my role is to provide not just surgical precision, but clinical clarity. Meningiomas, while technically “brain tumours,” are unique in their pathology and often carry a far more optimistic prognosis than patients initially fear.

What is a Meningioma?

A meningioma is an extra-axial tumour, meaning it arises from the meninges—the protective membranes enveloping the brain and spinal cord—rather than the brain tissue itself. Because they typically grow by displacement rather than invasion, complete surgical resection is often achievable, frequently resulting in a functional cure.

Meningiomas represent the most common primary central nervous system (CNS) tumour, accounting for approximately 37% of all reported cases.

Clinical Presentation and Symptoms

Symptoms are rarely acute; they typically manifest insidiously as the tumour gradually exerts pressure on adjacent neural structures. The presentation depends entirely on the anatomical location:

• Convexity: Often presents with focal seizures or progressive motor/sensory deficits.
• Parasagittal & Falcine: May lead to bilateral leg weakness or gait disturbances.
• Sphenoid Wing: Can cause visual field defects, proptosis (bulging of the eye), or facial numbness.
• Olfactory Groove: Gradual loss of smell (anosmia) and subtle personality changes (often mistaken for depression or ageing).
• Posterior Fossa: May involve cranial nerves, leading to hearing loss, vertigo, or swallowing difficulties.

WHO Classification and Grading

Pathological grading is critical for determining the long-term management strategy:

1. WHO Grade I (Benign - ~80%): Slow-growing with a low risk of recurrence. Excellent long-term prognosis following surgical resection.
2. WHO Grade II (Atypical - ~15-18%): More cellularly active with a higher propensity for recurrence. Adjuvant radiotherapy may be considered.
3. WHO Grade III (Anaplastic/Malignant - ~2-3%): Aggressive tumours requiring intensive multi-modal therapy (surgery followed by radiotherapy).

The Gold Standard: Diagnosis

Magnetic Resonance Imaging (MRI) with gadolinium contrast remains the definitive diagnostic tool. We look for the classic “dural tail” sign—a thickening of the adjacent dura mater—which, combined with its well-demarcated borders, allows for a confident pre-operative diagnosis.

Treatment Philosophy: Precision and Discipline

My approach to meningioma management is rooted in the Oxford tradition: meticulous planning followed by disciplined execution.

1. Active Surveillance (Watchful Waiting)

For small, asymptomatic tumours discovered incidentally, a “wait and scan” approach is often the most prudent course. We monitor the tumour with serial MRIs every 6 to 12 months.

2. Surgical Resection (Craniotomy)

Surgery is indicated for symptomatic tumours or those showing documented growth. The goal is a Simpson Grade I resection—complete removal of the tumour, its dural attachment, and any affected bone.

To ensure the highest safety standards, I routinely employ:

• Neuro-navigation: GPS-like precision for the smallest possible incisions.
• Intraoperative Neurophysiological Monitoring (IOM): Real-time tracking of nerve function to protect speech and movement.

3. Stereotactic Radiosurgery (SRS)

Technologies like Gamma Knife or CyberKnife are excellent alternatives for tumours in surgically high-risk areas (e.g., the skull base) or for patients who are not candidates for general anaesthesia.

Recovery and Prognosis

The prognosis for a Grade I meningioma is exceptionally high. Following a successful craniotomy, patients typically spend 4–5 days in the hospital. A return to professional life is usually feasible within 6–8 weeks.

Frequently Asked Questions

Is a meningioma cancer? Most meningiomas (around 80%) are WHO Grade I — benign, slow-growing, and not cancer in the sense most people fear. They arise from the meninges, the protective membranes around the brain, rather than from brain tissue itself, and a complete surgical resection often results in a functional cure.

What is a Simpson Grade resection? The Simpson Grade describes how completely a meningioma is removed during surgery. A Simpson Grade I resection — complete removal of the tumour, its dural attachment, and any affected bone — carries a significantly lower recurrence rate than a subtotal (Grade III) removal, which is why surgical thoroughness is the primary determinant of long-term outcome.

What are the treatment options for meningioma? Options include active surveillance with serial MRI for small, asymptomatic tumours; surgical resection (craniotomy) using neuro-navigation and intraoperative neurophysiological monitoring for symptomatic or growing tumours; and stereotactic radiosurgery (Gamma Knife or CyberKnife) for tumours in surgically high-risk locations or patients unfit for general anaesthesia.

Is it hereditary? The vast majority of meningiomas are sporadic. However, multiple tumours may be associated with genetic conditions such as Neurofibromatosis Type 2 (NF2).

Can the tumour return? Recurrence depends on the “Simpson Grade” of the initial surgery. A Grade I resection has a significantly lower recurrence rate than a Grade III subtotal removal. This is why surgical thoroughness is paramount.

A diagnosis is the beginning of a management plan, not a conclusion. If you or a loved one are facing this diagnosis, clarity is your strongest ally.

Book a consultation at KPJ Tawakkal Specialist Hospital to discuss your options with precision and care.